State Board of Administration of Florida Retirement System continued to hold its position in Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,498 shares of the biotechnology company’s stock at the end of the first quarter. State Board of Administration of Florida Retirement System owned about 0.05% of Exelixis worth $3,240,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of the stock. C WorldWide Group Holding A S raised its stake in shares of Exelixis by 19.7% in the first quarter. C WorldWide Group Holding A S now owns 555,458 shares of the biotechnology company’s stock worth $12,037,000 after buying an additional 91,230 shares during the last quarter. Klingenstein Fields & Co. LLC bought a new position in shares of Exelixis during the first quarter worth about $217,000. Great West Life Assurance Co. Can increased its position in shares of Exelixis by 26.9% in the first quarter. Great West Life Assurance Co. Can now owns 28,342 shares of the biotechnology company’s stock worth $613,000 after buying an additional 6,000 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Exelixis by 167.1% in the first quarter. Wells Fargo & Company MN now owns 1,460,194 shares of the biotechnology company’s stock worth $31,642,000 after buying an additional 913,454 shares during the period. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in Exelixis by 237.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 5,041,260 shares of the biotechnology company’s stock worth $109,244,000 after buying an additional 3,547,665 shares during the period. Institutional investors own 80.69% of the company’s stock.
Exelixis, Inc. (EXEL) traded up 12.15% during mid-day trading on Monday, hitting $21.60. The stock had a trading volume of 5,709,876 shares. The stock has a market cap of $6.32 billion, a price-to-earnings ratio of 1028.57 and a beta of 1.98. Exelixis, Inc. has a 12-month low of $7.20 and a 12-month high of $24.85. The company has a 50-day moving average of $20.44 and a 200-day moving average of $19.81.
Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.06. Exelixis had a net margin of 1.37% and a return on equity of 126.82%. The business had revenue of $80.90 million during the quarter, compared to analysts’ expectations of $65.23 million. During the same quarter last year, the company earned ($0.27) earnings per share. The firm’s revenue was up 425.3% on a year-over-year basis. On average, analysts anticipate that Exelixis, Inc. will post $0.18 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “State Board of Administration of Florida Retirement System Has $3,240,000 Position in Exelixis, Inc. (EXEL)” was reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/markets/exelixis-inc-exel-stake-maintained-by-state-board-of-administration-of-florida-retirement-system-updated-updated/862902.html.
EXEL has been the subject of several research reports. Stifel Nicolaus cut Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price target for the company. in a research report on Tuesday, February 28th. They noted that the move was a valuation call. Zacks Investment Research lowered Exelixis from a “buy” rating to a “hold” rating in a research note on Wednesday, March 1st. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Wednesday, March 1st. Cann started coverage on Exelixis in a research note on Wednesday, March 15th. They set a “positive” rating on the stock. Finally, Oppenheimer Holdings, Inc. started coverage on Exelixis in a research report on Thursday, March 16th. They issued a “market perform” rating on the stock. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $18.37.
In other Exelixis news, Director Jack L. Wyszomierski sold 5,150 shares of the firm’s stock in a transaction dated Friday, March 31st. The shares were sold at an average price of $21.57, for a total transaction of $111,085.50. Following the completion of the transaction, the director now owns 78,110 shares in the company, valued at $1,684,832.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total transaction of $92,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 755,468 shares of company stock valued at $16,630,440. 5.10% of the stock is owned by corporate insiders.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with our FREE daily email newsletter.